Individualized Functional Connectivity Targeting in aiTBS for Depression
| 适应症 | Depressive Disorder, Major, Depression, Mood Disorders, Mental Disorder |
|---|---|
| 分期 | 2期 |
| 申办方 | Brigham and Women's Hospital |
| 状态 | 已完成 |
| 受试者人数 | 40 人 |
| 干预（药物） | transcranial magnetic stimulation |
| 开始日期 | 2023年7月15日 |
| 完成日期 | 2025年3月17日 |
| 结果公布日 | 2026年7月7日 |
摘要
The goal of this clinical trial is to estimate the importance of neuroimaging in accelerated intermittent theta burst stimulation (aiTBS) for depression. Participants will receive aiTBS treatment, but they will not know if their treatment spot was found with neuroimaging or head measurements.
Montgomery-Åsberg Depression Rating Scale (MADRS)
| Connectivity-based Targeting | 35 Scores on scale |
|---|---|
| Scalp-based Targeting | 31 Scores on scale |
| Connectivity-based Targeting | 6 Scores on scale |
| Scalp-based Targeting | 11 Scores on scale |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital